

## **ARCI Update to Controlled Therapeutic Medication Schedule Posted:**

Lexington, KY - The revisions to its racing regulatory standards that were adopted by the Association of Racing Commissioners International (ARCI) at its meeting last month in New Orleans were formally posted today.

The ARCI also expanded its Controlled Therapeutic Medication Schedule to include and set regulatory thresholds for the following four medications: Cimetidine, Ranitidine, Cetirizine and Guaifenesin.

Additionally, regulatory thresholds for Xylazine and Omeprazole were modified based on new information and research not available when the schedule was initially adopted. The Xylazine and the Omeprazole thresholds were adjusted based upon studies conducted at the University of California at Davis, funded by the Kentucky Equine Drug Research Council, and coordinated through the Racing Medication and Testing Consortium.

ARCI Model Rules serve as a guide to jurisdictions in the making of racing regulatory policy. In some instances, portions of the ARCI Model Rules have the force of law by virtue of statutes or rules incorporating them "by reference". This means that when the ARCI adopts a rule, it automatically becomes the applicable policy in jurisdictions that have done that. The New Jersey Racing Commission has incorporated by reference only the first two columns ("Controlled Therapeutic Medication" and "Threshold") of the Controlled Therapeutic Medication Schedule, as amended and supplemented by the ARCI.

Link to Version 3.0 of the Controlled Therapeutic Schedule:

[https://drive.google.com/file/d/0B2HwTiDKu\\_FHblUwYm5Rc3JxMUE/view?usp=sharing](https://drive.google.com/file/d/0B2HwTiDKu_FHblUwYm5Rc3JxMUE/view?usp=sharing)